Asad Dean, MD

An expert discusses how current ITP treatments like corticosteroids, rituximab, and fostamatinib have significant tolerability issues and fail to provide sustained platelet responses or address quality of life concerns.

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase inhibitor, targets the autoimmune pathophysiology of ITP by modulating B cells, macrophages, and reducing pro-inflammatory cytokines.